[go: up one dir, main page]

WO2019035057A3 - Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci - Google Patents

Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci Download PDF

Info

Publication number
WO2019035057A3
WO2019035057A3 PCT/IB2018/056200 IB2018056200W WO2019035057A3 WO 2019035057 A3 WO2019035057 A3 WO 2019035057A3 IB 2018056200 W IB2018056200 W IB 2018056200W WO 2019035057 A3 WO2019035057 A3 WO 2019035057A3
Authority
WO
WIPO (PCT)
Prior art keywords
exosome
preparing
exosomes
delivering
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/056200
Other languages
English (en)
Other versions
WO2019035057A2 (fr
Inventor
Chulhee Choi
Nambin YIM
Hojun CHOI
Kyungsun CHOI
Seung-Wook RYU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ilias Biologics Inc
Original Assignee
Cellex Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65361814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2019035057(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA3073162A priority Critical patent/CA3073162C/fr
Priority to JP2020530742A priority patent/JP7224352B2/ja
Priority to US16/639,740 priority patent/US20200206360A1/en
Priority to EP18846900.1A priority patent/EP3668552A4/fr
Priority to CN201880067512.6A priority patent/CN111629761B/zh
Priority to AU2018316803A priority patent/AU2018316803B2/en
Application filed by Cellex Life Sciences Inc filed Critical Cellex Life Sciences Inc
Publication of WO2019035057A2 publication Critical patent/WO2019035057A2/fr
Publication of WO2019035057A3 publication Critical patent/WO2019035057A3/fr
Priority to IL272684A priority patent/IL272684B2/en
Anticipated expiration legal-status Critical
Priority to AU2021250906A priority patent/AU2021250906B2/en
Priority to US18/412,403 priority patent/US12133879B2/en
Priority to US18/887,997 priority patent/US20250009845A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé de production d'un exosome qui transfère une substance active spécifiquement à une cible, et l'exosome produit par ledit procédé; un procédé d'administration de la substance active au tissu cible à l'aide de l'exosome; une composition pharmaceutique pour l'administration de la substance active comprenant l'exosome en tant que principe actif; et une composition pour préparer l'exosome comprenant un vecteur d'expression où le peptide cible est inséré dans une partie extracellulaire d'une protéine transmembranaire.
PCT/IB2018/056200 2015-05-04 2018-08-16 Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci Ceased WO2019035057A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA3073162A CA3073162C (fr) 2017-08-17 2018-08-16 Exosomes pour administration specifique a une cible et procedes de preparation et d'administration de ceux-ci
JP2020530742A JP7224352B2 (ja) 2017-08-17 2018-08-16 標的特異的伝達のためのエクソソーム及びこれを製造及び伝達する方法
US16/639,740 US20200206360A1 (en) 2017-08-17 2018-08-16 Exosomes for target specific delivery and methods for preparing and delivering the same
EP18846900.1A EP3668552A4 (fr) 2017-08-17 2018-08-16 Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci
CN201880067512.6A CN111629761B (zh) 2017-08-17 2018-08-16 用于靶特异性递送的外泌体以及用于制备和递送该外泌体的方法
AU2018316803A AU2018316803B2 (en) 2017-08-17 2018-08-16 Exosomes for target specific delivery and methods for preparing and delivering the same
IL272684A IL272684B2 (en) 2017-08-17 2020-02-16 Exosomes for target-specific delivery and methods for their preparation and delivery
AU2021250906A AU2021250906B2 (en) 2017-08-17 2021-10-13 Exosomes for target specific delivery and methods for preparing and delivering the same
US18/412,403 US12133879B2 (en) 2015-05-04 2024-01-12 Exosomes for target specific delivery and methods for preparing and delivering the same
US18/887,997 US20250009845A1 (en) 2015-05-04 2024-09-17 Exosomes for target specific delivery and methods for preparing and delivering the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170104171 2017-08-17
KR10-2017-0104171 2017-08-17
US201862659816P 2018-04-19 2018-04-19
US62/659,816 2018-04-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/004750 Continuation-In-Part WO2016178532A1 (fr) 2015-05-04 2016-05-04 Procédé de production d'exosome comprenant une protéine cible et procédé de transfert de protéine cible dans le cytoplasme à l'aide de l'exosome produit par le procédé de production

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/639,740 A-371-Of-International US20200206360A1 (en) 2017-08-17 2018-08-16 Exosomes for target specific delivery and methods for preparing and delivering the same
US18/412,403 Continuation-In-Part US12133879B2 (en) 2015-05-04 2024-01-12 Exosomes for target specific delivery and methods for preparing and delivering the same

Publications (2)

Publication Number Publication Date
WO2019035057A2 WO2019035057A2 (fr) 2019-02-21
WO2019035057A3 true WO2019035057A3 (fr) 2019-04-25

Family

ID=65361814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/056200 Ceased WO2019035057A2 (fr) 2015-05-04 2018-08-16 Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci

Country Status (2)

Country Link
KR (1) KR102100420B1 (fr)
WO (1) WO2019035057A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102125567B1 (ko) * 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 식물 엑소좀의 대량 생산 방법
US20210093567A1 (en) * 2019-08-06 2021-04-01 Ohio State Innovation Foundation Therapeutic extracellular vesicles
WO2021045501A1 (fr) * 2019-09-02 2021-03-11 경북대학교 산학협력단 Composition pour la prévention ou le traitement du cancer, contenant, en tant que principe actif, des vésicules extracellulaires exprimant l'il-2 en surface
JP2023512562A (ja) * 2020-02-05 2023-03-27 ダイアデム バイオセラピューティクス インコーポレイテッド 人工シナプス
US20230126199A1 (en) * 2020-02-28 2023-04-27 National University Corporation Kanazawa University Immunoregulatory method, nucleic acid composition for immunoregulation and use thereof
EP4117717A1 (fr) * 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Vésicules extracellulaires pour le traitement de troubles neurologiques
CN113679850B (zh) * 2020-05-19 2023-05-19 首都医科大学附属北京天坛医院 一种被靶向修饰且装载有药物的外泌体及其制备方法和应用
KR102341138B1 (ko) * 2020-05-31 2021-12-21 주식회사 엑소코바이오 엑소좀의 막단백질 변이체를 포함하는 엑소좀 및 이의 제조방법
KR102699872B1 (ko) * 2021-04-29 2024-08-29 주식회사 서지넥스 약물전달물질로서의 대장암 특이적 표적 엑소좀 조성물 및 이의 용도
KR102699871B1 (ko) * 2021-04-29 2024-08-29 주식회사 서지넥스 약물전달물질로서의 간세포암 특이적 표적 엑소좀 조성물 및 이의 용도
KR102620197B1 (ko) * 2021-04-30 2024-01-02 가톨릭대학교 산학협력단 약물전달물질로서의 대장암 특이적 표적 엑소좀 조성물 및 이의 용도
KR102632530B1 (ko) * 2021-05-24 2024-02-02 가톨릭대학교 산학협력단 약물전달물질로서의 위암 특이적 표적 엑소좀 조성물 및 이의 용도
KR20230013009A (ko) 2021-07-16 2023-01-26 서울대학교산학협력단 세포외 소포체 및 그 제조방법
KR20250040552A (ko) * 2023-09-14 2025-03-24 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002956A1 (fr) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Système de distribution d'exosome
US20160137716A1 (en) * 2013-04-12 2016-05-19 Samir El Andaloussi Therapeutic delivery vesicles
KR20160130937A (ko) * 2015-05-04 2016-11-15 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160137716A1 (en) * 2013-04-12 2016-05-19 Samir El Andaloussi Therapeutic delivery vesicles
WO2015002956A1 (fr) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Système de distribution d'exosome
KR20160130937A (ko) * 2015-05-04 2016-11-15 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HA, DINH ET AL.: "Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges", ACTA PHARMACEUTICA SINICA B, vol. 6, no. 4, 2016, pages 287 - 296, XP055303644, DOI: doi:10.1016/j.apsb.2016.02.001 *
KOTMAKCI, MUSTAFA ET AL.: "Extracellular vesicles as natural nanosized delivery systems for small-molecule drugs and genetic material: steps towards the future nanomedicines", JOURNAL OF PHARMACY & PHARMACEUTICAL SCIENCES, vol. 18, no. 3, 2015, pages 396 - 413, XP055594743 *

Also Published As

Publication number Publication date
KR102100420B1 (ko) 2020-04-13
KR20190019872A (ko) 2019-02-27
WO2019035057A2 (fr) 2019-02-21
KR102100420B9 (ko) 2022-01-19

Similar Documents

Publication Publication Date Title
WO2019035057A3 (fr) Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci
EA201991299A1 (ru) Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов
MX2021000196A (es) Vesículas de leche para usar en la administración de agentes biológicos.
EP4410317A3 (fr) Nouveaux lipides carbonyle et formulations de nanoparticules lipidiques pour l'administration d'acides nucléiques
SG11201810270SA (en) Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
PH12021551635A1 (en) Hexone glucokinase inhibitor and use thereof
CA3016457A1 (fr) Nanovaccin activant sting pour l'immunotherapie
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
Wang et al. Cutting edge: the heat shock protein gp96 activates inflammasome-signaling platforms in APCs
CY1118826T1 (el) Διαδικασια για την κατασκευη ενος φαρμακευτικου σκευασματος που περιεχει glatiramer acetate
JP2016510729A (ja) 薬剤のデリバリーのためのジスルフィド化合物
BR112018012641A2 (pt) molécula de penetração de célula portadora de fármaco, métodos para facilitar a incorporação de um composto biologicamente ativo (bac) em uma célula, para melhorar a biodisponibilidade de um fármaco ou bac, para introduzir um fármaco ou bac em um sítio e para alterar a expressão de um gene endógeno ou exógeno, e, composição.
KR102144323B1 (ko) 글루타티온 다이설파이드 및 글루타티온 다이설파이드 s-옥사이드를 포함한 제약학적 조성물
Liu et al. Interruption of hepatocyte growth factor signaling augmented oridonin-induced death in human non-small cell lung cancer A549 cells via c-met-nuclear factor-κB-cyclooxygenase-2 and c-Met-Bcl-2-caspase-3 pathways
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
MX2021009526A (es) Composiciones para suministro farmacologico, para la administracion ocular de agentes terapeuticos, y metodos de uso de las mismas.
MX2021012994A (es) Administracion heterologa de vacunas tau.
Busnardo et al. Ionotropic glutamate receptors in hypothalamic paraventricular and supraoptic nuclei mediate vasopressin and oxytocin release in unanesthetized rats
JOP20210185A1 (ar) مركبات هالو-آلِّيلامين واستخدامها
IL307997A (en) Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
Mameli et al. Bromelain: An overview of applications in medicine and dentistry
MA53189A1 (fr) Composition pharmaceutique destinée au traitement de l'anémie aplasique
MX2020002247A (es) Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene.
EP3496737A1 (fr) Protéines de fusion apom-fc, leurs complexes avec la sphingosine 1-phosphate (s1p), et méthodes de traitement de maladies vasculaires et non vasculaires
CN103980353A (zh) 一种疏水蛋白及其组成的药物制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18846900

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3073162

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020530742

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018846900

Country of ref document: EP

Effective date: 20200317

ENP Entry into the national phase

Ref document number: 2018316803

Country of ref document: AU

Date of ref document: 20180816

Kind code of ref document: A